FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Was

0 ,		_,,,	.,	••	_ `
shington.	D.C. 20	0549			

OMB APPROVAL	

Section	his box if no log 16. Form 4 or ons may conting ion 1(b).	Form 5	STA			oursua	ent to Section 16	6(a)	of the S	Securit	NEFICIAL ties Exchange A mpany Act of 19	oct of 1934		IP	Estin	Number: nated ave s per resp	rage burde	3235-0287 en 0.5		
1 Name and Address of Reporting Person* 2. Iss				. Issue	er Name and Ti	cker	or Trad	ling S			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner									
(Last) (First) (Middle) C/O MPM ASSET MANAGEMENT					. Date 8/03/	of Earliest Trar 2007	nsac	tion (Mo	onth/D	ay/Year)		Officer (give title Other (specify below) below)								
200 CLARENDON ST., 54TH FLOOR (Street)						4. If Amendment, Date of Original Filed (Month/Day/Year) 08/07/2007								6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person						
BOSTON		IA 	02116				2007							X Form filed by More than One Reporting Person						
(City)	(5	state)	(Zip)	n-Deri	vat	ive S	Securities A) C (1	uired	Dis	sposed of, o	r Bene	ficially (Owned						
1. Title of S	ecurity (Inst		rable 1 - No	2. Trans Date (Month/I	actio	on	2A. Deemed Execution Date if any (Month/Day/Ye	е,	3. Transa Code (I	ction	4. Securities A Disposed Of (D	cquired (A) or	5. Amount of Securities Beneficially Owned Follo		6. Own Form: I (D) or I (I) (Inst	Direct ndirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D)	Price	Transaction (Instr. 3 and				,		
Common	Stock			08/03	3/20	007			J ⁽¹⁾		3,239,443(1)	A	(1)	3,364,4	143		Ι	See Footnote ⁽²⁾		
			7/2007				P		125,000(3)	A	\$7.7					See Footnote ⁽⁴⁾				
			Table II -								osed of, or convertible			vned						
1. Title of Derivative Security (Instr. 3) Price of Derivative Security		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Code (I			5. Number of Derivative Securities Acquired (A) o Disposed of (D (Instr. 3, 4 and	Derivative Expiration Securities (Month/Day Acquired (A) or		Date ⁽ /Year)	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Num derivat Securit Benefic Owned Follow	ive Cies Ficially Ding (I	10. Ownersl Form: Direct (E or Indire (I) (Instr.	Beneficia Ownershi ct (Instr. 4)			
				Cod	de	v	(A)	(D)	Date Exerc	cisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction((Instr. 4)					
8% Convertible Note	\$10	08/03/2007		J ⁽⁵	5)		\$4,709,553.61		((6)	08/03/2009	Common Stock	470,953	(5)	\$4,709	,553.61	I	See Footnote ⁽		
Stock Option (Right to Buy)	\$4.22	08/03/2007		A			1,104		(8)		01/18/2016	Common Stock	1,104	\$0	1,	104	I	See Footnote ⁽⁾		
1. Name an EVNIN		Reporting Person*		,									,							
		(First) //ANAGEMENT ST., 54TH FLOO		e)																
(Street) BOSTON	I	MA	02116	5																
(City)		(State)	(Zip)																	
		Reporting Person*																		
(Last)		(First)	(Middle	e)																

1. Name and Address of Reporting Person^{\star}

C/O MPM ASSET MANAGEMENT 200 CLARENDON ST., 54TH FLOOR

MA

(State)

02116

(Zip)

HENNER DENNIS

(Street) **BOSTON**

(Last)	(First)	(Middle)					
C/O MPM ASSET M							
200 CLARENDON ST., 54TH FLOOR							
(Street)							
BOSTON	MA	02116					
(City)	(State)	(Zip)					
1. Name and Address of STEINMETZ M							
(Last)	(First)	(Middle)					
C/O MPM ASSET M	MANAGEMENT						
200 CLARENDON	ST., 54TH FLOOR						
(Street)							
BOSTON	MA	02116					
(City)	(State)	(Zip)					
1. Name and Address of							
GADICKE ANS	BERT						
(Last)	(First)	(Middle)					
C/O MPM ASSET M	MANAGEMENT						
200 CLARENDON	ST., 54TH FLOOR						
(Street)							
BOSTON	MA	02116					
(City)	(State)	(Zip)					
1. Name and Address of WHEELER KUI							
(Last)	(First)	(Middle)					
C/O MPM ASSET M	MANAGEMENT						
200 CLARENDON	ST., 54TH FLOOR						
(Street)							
BOSTON	MA	02116					
(City)	(State)	(7in)					
(City)	(State)	(Zip)					
I 1 Name and ∆ddress of							
SIMON NICHO	Reporting Person* LAS J III						
		(Middle)					
SIMON NICHO	(First)	(Middle)					
SIMON NICHO	LAS J III (First) MANAGEMENT	(Middle)					
(Last) C/O MPM ASSET M	LAS J III (First) MANAGEMENT	(Middle)					
(Last) C/O MPM ASSET M 200 CLARENDON S	LAS J III (First) MANAGEMENT	(Middle) 02116					
(Last) C/O MPM ASSET M 200 CLARENDON S (Street)	(First) MANAGEMENT ST., 54TH FLOOR						

Explanation of Responses:

- 1. The shares were received in exchange for an aggregate of 17,933,960 shares of Series B and Series C Convertible Preferred Stock of PharmAthene, Inc. in connection with the acquisition of PharmAthene, Inc. through the merger of the Issuer's subsidiary into PharmAthene, Inc. (the "Merger"). The shares were received as follows: 2,686,710 by MPM BioVentures III-QP, L.P. ("BV III QP"), 180,663 by MPM BioVentures III, L.P. ("BV III"), 63,871 by MPM Asset Management Investors 2004 BVIII LLC ("AM 2004"), 81,147 by MPM BioVentures III Parallel Fund, L.P. ("BV Parallel") and 227,052 by MPM BioVentures III GP L.P. ("MPM III GP") and MPM BioVentures III LLC ("MPM III LLC") are the direct and indirect general partners of BV III QP, BV III and BV Parallel and BV KG. Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon III, Michael Steinmetz and Kurt Wheeler are the members of MPM III LLC and AM 2004. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
- 2. The shares are held as follows: 2,790,382 by BV III QP, 187,634 by BV III, 66,336 by AM 2004, 84,278 by BV Parallel and 235,813 by BV KG. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
- 3. The shares were purchased as follows: 103,672 by BV III QP, 6,971 by BV III, 2,465 by AM 2004, 3,131 by BV Parallel and 8,761 by BV KG. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
- 4. The shares are held as follows: 2,894,054 by BV III QP, 194,605 by BV III, 68,801 by AM 2004, 87,409 by BV Parallel and 244,574 by BV KG. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
- 5. The notes were received in the Merger in cancellation of convertible promissory notes of PharmAthene, Inc. in the aggregate principal amount of \$4,425,867.53, plus accrued interest thereon.
- ${\it 6. Immediately\ convertible\ into\ shares\ of\ Common\ Stock\ of\ the\ Issuer\ at\ the\ rate\ of\ \$10.00\ per\ share.}$
- 7. The notes are held as follows: \$3,905,976.55 by BV III QP, \$262,651.82 by BV III, \$92,858.30 by AM 2004, \$117,974.13 by BV Parallel and \$330,092.81 by BV KG. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
- $8.\ 25\%\ of\ the\ shares\ underlying\ the\ option\ shall\ vest\ each\ year\ commencing\ on\ the\ first\ anniversary\ of\ January\ 18,\ 2006.$
- 9. The option is held by Ansbert Gadicke.

Remarks:

See Form 4/A for MPM BioVentures III-QP, L.P. filed simultaneously herewith for additional members of this joint filing. This amendment is being filed to reflect the additional shares issued pursuant to a post-closing adjustment in connection with the Merger. This information was not available at the time of the original filing.

<u>/s/ Luke Evnin</u>	10/03/2007
/s/ Nicholas Galakatos	10/03/2007
/s/ Dennis Henner	10/03/2007
/s/ Michael Steinmetz	10/03/2007
/s/ Ansbert Gadicke	10/03/2007
/s/ Kurt Wheeler	10/03/2007
/s/ Nicholas J. Simon, III	10/03/2007
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).